

Attorney Docket No. 2300-0363.01 (PP00363.115)

PATENT

Express Mail Label No.: EL 985 780 159 US

Date of Deposit: 10/28/03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of SCARLATO et al.

Serial No.: CON of 09/302,626

Examiner: Unassigned

Confirmation No.:

Art Unit: Unassigned

Filed: On even date herewith

For: MENINGOCOCCAL ANTIGENS

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.97(b)**

In accordance with the duty of disclosure set forth in 37 C.F.R. §1.56,
Applicant(s) hereby submits the following information in conformance with 37 C.F.R.
§§1.97 and 1.98.

- ☐ Pursuant to 37 C.F.R. §1.98, a copy of each document cited in the attached Form PTO/SB/08 is enclosed.
- ☒ No copies of the publications listed on the attached Form PTO/SB/08A are being provided pursuant to 37 C.F.R. §1.98(d) because the publications were previously cited by or submitted to the Office in prior Application Serial No. 09/302,626 to which the above-identified application claims priority under 35 U.S.C. §120.
- ☐ Publication(s) _____ listed on the attached Form PTO/SB/08A were cited in a foreign search or examination report corresponding to _____ application serial no. _____ and mailed on _____.
- ☐ Enclosed is a copy of a non-English publication(s) _____. Pursuant to §609 of the M.P.E.P., Applicant submits the attached foreign search or examination report, which cites such non-English language publication(s).

- ☐ Enclosed is a copy of a non-English publication(s) _____. English language publication ____ (copy enclosed) claims priority from this non-English publication.
- ☐ Enclosed is an explanation of non-English publication(s) _____ for which an English translation is not available.
- ☐ Enclosed is an English translation of non-English publication(s) _____ cited in the attached Form PTO/SB/08A.
- ☐ Enclosed is a copy of pending patent Application Serial No. _____.

This Information Disclosure Statement is filed with the herein continuation application.

It is respectfully requested that the Examiner consider the above-noted information and return an initialed copy of the attached Form PTO/SB/08A to the undersigned.

Please direct all further written communications in this application to:


Alisa A. Harbin
Chiron Corporation
Intellectual Property – R440
P.O. Box 8097
Emeryville, CA 94662-8097.

Dated: 10/28/03

Respectfully submitted,

Chiron Corporation
Intellectual Property – R440
P.O. Box 8097
Emeryville, CA 94662-8097
Tel: (650) 493-3400
Fax: (650) 493-3440

By:


Roberta L. Robins
Reg. No. 33,208

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	CON of 09/302,626
				Filing Date	On even date herewith
				First Named Inventor	SCARLATO
				Group Art Unit	Unassigned
Examiner Name	Unassigned				
Sheet	2	of	3	Attorney Docket Number	2300-0363 (PP00363.115)

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	ALDEEN et al., "The meningococcal transferring-binding proteins 1 and 2 are both surface exposed and generate bactericidal antibodies capable of killing homologous and heterologous strains," <i>Vaccine</i> 14(1):49-53, 1996	
	C2	CONSTANTINO et al., "Development and phase I clinical testing of a conjugate vaccine against meningococcus A and C," <i>Vaccine</i> 10:691-698	
	C3	JAFARI et al., "Control and prevention of meningococcal disease: recommendations of the advisory committee on immunization practices (ACIP)," <i>MMWR</i> 46(RR-5):1-10, 1997	
	C4	LIEBERMAN et al., "Safety and immunogenicity of a serogroups A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children," <i>JAMA</i> 275(19):1499-1503, 1996	
	C5	PERKINS et al., "Control and prevention of serogroup C meningococcal disease: evaluation and management of suspected outbreaks: recommendations for the advisory committee on immunization practices (ACIP)," <i>MMWR</i> 46(RR-5):13-21, 1997	
	C6	POOLMAN, "Development of a meningococcal vaccine," <i>Infections agents and Disease</i> 4:13-28, 1995	
	C7	ROKBI et al., "Evaluation of recombinant transferring-binding protein B variants from Neisseria meningitidis for their ability to induce cross-reactive and bactericidal antibodies against antigenically diverse collection of serogroup B strains," <i>Infection and Immunity</i> 65(1):55-63, 1997	
	C8	ROKBI et al., "Heterogeneity of <i>tbpB</i> , the transferring-binding protein B gene, among serogroup B Neisseria meningitidis strains of the ET-5 complex," <i>Clinical and Diagnostic Lab. Immun.</i> 4(5):522-529, 1997	
	C9	ROMERO et al., "Current status of meningococcal group B vaccine candidates: capsular or noncapsular?" <i>Clinical Microbio. Reviews</i> 7(4):559-575, 1994	
	C10	SCHUCHAT et al., "Bacterial meningitis in the United States in 1995," <i>New England J. of Medicine</i> 337(14):970-976, 1997	
	C11	WEDEGE et al., "Human antibody response to a group B serotype 2a meningococcal vaccine determined by immunoblotting," <i>Infection and Immunity</i> 51(2):571-578, 1986	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.

² Applicant is to place a check mark here if English language Translation attached.

